Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies.

The global population remains vulnerable in the face of the next pandemic influenza virus outbreak, and reformulated vaccinations are administered annually to manage seasonal epidemics. Therefore, development of a new generation of vaccines is needed to generate broad and persistent immunity to infl...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Peter H Goff, Dirk Eggink, Christopher W Seibert, Rong Hai, Luis Martínez-Gil, Florian Krammer, Peter Palese
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24223176/pdf/?tool=EBI

Similar Items

An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains
by: Weina Sun, et al.
Published: (2019-09-01)

Induction of hemagglutinin stalk reactive antibodies by the administration of a live-attenuated influenza virus vaccine in children
by: Juan Manuel Carreño, et al.
Published: (2025-07-01)

Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses
by: Eduard Puente-Massaguer, et al.
Published: (2023-06-01)

A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates.
by: Florian Krammer, et al.
Published: (2012-01-01)

No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
by: Anders Madsen, et al.
Published: (2019-08-01)

Development and Assessment of a Pooled Serum as Candidate Standard to Measure Influenza A Virus Group 1 Hemagglutinin Stalk-Reactive Antibodies
by: Juan Manuel Carreño, et al.
Published: (2020-11-01)

Group 1 and group 2 hemagglutinin stalk antibody response according to age
by: Laura Sánchez-de Prada, et al.
Published: (2023-05-01)

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase
by: Kevin E. Ramos, et al.
Published: (2024-07-01)

Antibody Response to Influenza Hemagglutinin Conserved Stalk Domain after Sequential Immunization with Old Vaccine Strains
by: Alita Kongchanagul, et al.
Published: (2024-01-01)

Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV
by: Boitumelo M. Motsoeneng, et al.
Published: (2022-04-01)

Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination
by: Teresa Aydillo, et al.
Published: (2022-12-01)

Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.
by: Miriam Klausberger, et al.
Published: (2016-01-01)

Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants
by: Jenny E. Hernandez-Davies, et al.
Published: (2022-06-01)

Influenza A Virus Hemagglutinin Trimer, Head and Stem Proteins Identify and Quantify Different Hemagglutinin-Specific B Cell Subsets in Humans
by: Aafke Aartse, et al.
Published: (2021-07-01)

Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies
by: Clara J. Sei, et al.
Published: (2021-06-01)

Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model
by: Fatima Amanat, et al.
Published: (2019-01-01)

Correction for Ramos et al., “Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase”
by: Kevin E. Ramos, et al.
Published: (2025-04-01)

Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity against Influenza A Viruses in a Preclinical Ferret Model
by: Wen-Chun Liu, et al.
Published: (2021-01-01)

Correction: Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costs.
by: Ivan Kosik, et al.
Published: (2018-06-01)

Tethered Antigenic Suppression Shields the Hemagglutinin Head Domain and Refocuses the Antibody Response to the Stalk Domain
by: Donguk Kim, et al.
Published: (2025-01-01)

Monoclonal antibodies to hemagglutinin of influenza A/H7N3 virus (Orthomyxoviridae: Alphainfluenzavirus: Influenza A virus)
by: E. V. Sorokin, et al.
Published: (2021-07-01)

The generation of hemagglutinin monoclonal antibodies against H9N2 influenza virus
by: Yongcheng Duan, et al.
Published: (2023-11-01)

Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach
by: Irene González-Domínguez, et al.
Published: (2024-11-01)

Longitudinal Analysis of Neuraminidase and Hemagglutinin Antibodies to Influenza A Viruses after Immunization with Seasonal Inactivated Influenza Vaccines
by: Mariia V. Sergeeva, et al.
Published: (2023-11-01)

Advancing universal influenza vaccines: insights from cellular immunity targeting the conserved hemagglutinin stalk domain in humans
by: Chunhong Dong, et al.
Published: (2024-06-01)

Introduction of Cysteines in the Stalk Domain of Recombinant Influenza Virus N1 Neuraminidase Enhances Protein Stability and Immunogenicity in Mice
by: Shirin Strohmeier, et al.
Published: (2021-04-01)

Incidence of Circulating Antibodies Against Hemagglutinin of Influenza Viruses in Epidemic Season 2023/2024 in Poland
by: Katarzyna Kondratiuk, et al.
Published: (2025-07-01)

Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses
by: Arne Matthys, et al.
Published: (2025-07-01)

Occurrence of Circulating Antibodies against the Hemagglutinins of Influenza Viruses in the 2022/2023 Epidemic Season in Poland
by: Katarzyna Kondratiuk, et al.
Published: (2024-07-01)

Prevalence of circulating antibodies against hemagglutinin of influenza viruses in epidemic season 2021/2022 in Poland
by: Katarzyna Kondratiuk, et al.
Published: (2024-02-01)

Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin
by: Sabari Nath Neerukonda, et al.
Published: (2020-07-01)

Broad cross-reactive IgG responses elicited by adjuvanted vaccination with recombinant influenza hemagglutinin (rHA) in ferrets and mice.
by: Jiong Wang, et al.
Published: (2018-01-01)

Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin
by: Shuwen Liu, et al.
Published: (2013-01-01)

Features of influenza virus hemagglutinin genes and their recoding possibilities
by: Eugene P. Kharchenko
Published: (2024-10-01)

Squalene-Based Influenza Vaccine Adjuvants and Their Impact on the Hemagglutinin-Specific B Cell Response
by: Phuong Nguyen-Contant, et al.
Published: (2021-03-01)

Mastoparan-7 adjuvanted COBRA H1 and H3 hemagglutinin influenza vaccines
by: Pedro L. Sanchez, et al.
Published: (2024-06-01)

Advax-SM™-Adjuvanted COBRA (H1/H3) Hemagglutinin Influenza Vaccines
by: Pedro L. Sanchez, et al.
Published: (2024-04-01)

Adjuvant-Mediated Differences in Antibody Responses to Computationally Optimized Hemagglutinin and Neuraminidase Vaccines
by: Kaito Nagashima, et al.
Published: (2023-01-01)

Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses.
by: Yuval Avnir, et al.
Published: (2014-05-01)

Designed nanoparticles elicit cross-reactive antibody responses to conserved influenza virus hemagglutinin stem epitopes.
by: Dustin M McCraw, et al.
Published: (2023-08-01)